221 related articles for article (PubMed ID: 28657611)
1. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
[TBL] [Abstract][Full Text] [Related]
2. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
3. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
Front Immunol; 2017; 8():1911. PubMed ID: 29375561
[TBL] [Abstract][Full Text] [Related]
4. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
[TBL] [Abstract][Full Text] [Related]
5. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
[TBL] [Abstract][Full Text] [Related]
6. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
7. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
[TBL] [Abstract][Full Text] [Related]
10. CSPG4 in cancer: multiple roles.
Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
[TBL] [Abstract][Full Text] [Related]
11. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
12. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
13. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
Kurokawa T; Imai K
Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
[TBL] [Abstract][Full Text] [Related]
14. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
15. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
Javaid S; Terai K; Dudek AZ
Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
[TBL] [Abstract][Full Text] [Related]
16. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen.
Bluemel C; Hausmann S; Fluhr P; Sriskandarajah M; Stallcup WB; Baeuerle PA; Kufer P
Cancer Immunol Immunother; 2010 Aug; 59(8):1197-209. PubMed ID: 20309546
[TBL] [Abstract][Full Text] [Related]
17. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
18. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
[TBL] [Abstract][Full Text] [Related]
19. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
[TBL] [Abstract][Full Text] [Related]
20. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
